Is there an age limit on hormone therapy? Timing, the 10-year window, and HT after 60 and 65.

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 12, 2026 · Updated November 12, 2026

If you are nearing 60, already past 65, or considering hormone therapy (HT), you may have heard there is a hard cutoff: start before 60, and stop by 65. That shorthand is common. It is not quite what the evidence and current guidance say.

Timing does matter, especially when therapy is started. A Study of Women's Health Across the Nation (SWAN) analysis, published in JAMA Internal Medicine in September 2026, estimated a lower cardiovascular risk among midlife women with hot flashes or night sweats who started hormone therapy closer to menopause. The authors were explicit: this is observational research, residual confounding is possible, and the findings should not be used to support hormone therapy for preventing heart disease.

We recently walked through a preliminary November heart-outcomes abstract—a different study, which we do not repeat here. This post asks whether FDA labeling and ACOG guidance set an age limit, what they say—and don't say—about continuing after 60 or 65, and what to ask a clinician. We first wrote about this SWAN analysis in September.

What the SWAN analysis found about timing

The figures below come from the paper's abstract and Key Points. The full article is paywalled; we did not use news summaries for these numbers.

Using SWAN cohort data (1997–2017)—a multiethnic, multicenter, longitudinal study of the menopause transition—researchers emulated a sequence of target trials. Eligible women had self-reported hot flashes and/or night sweats over the past two weeks, were free of cardiovascular disease, and had not used menopausal hormone therapy before. Of 2,737 eligible women, 755 started systemic estrogen, with or without a progestogen, verified from medication containers, at a mean age of 53.7 years (standard deviation, 4.6). Over 20 years of follow-up, 224 fatal and nonfatal cardiovascular events occurred (myocardial infarction, stroke, heart failure, and revascularization, self-reported, plus cardiovascular deaths from death certificates).

The estimated adjusted hazard ratio (aHR) of cardiovascular events for starting therapy versus not starting was 0.78 (95% CI, 0.62–0.98)—an estimated 22% lower risk, in the authors' wording. Among women who started 10 or fewer years from the onset of menopause, the estimated aHR was 0.73 (95% CI, 0.58–0.93). Among those who started more than 10 years from the onset of menopause, it was 1.53 (95% CI, 0.66–3.52), a wide interval that includes both lower and higher risk, so there is no clear effect in that group (P for interaction, .02).

Race and ethnicity also modified the effect: among Black women the estimated aHR was 0.51 (95% CI, 0.33–0.81); no clear effects were observed in White women or women of other races (P for interaction = .007). Those estimates, the authors say, still warrant caution and should not be used to support hormone therapy for prevention in any group. This was a study of when therapy was started, in a midlife cohort—not a trial of whether to stop at 60 or 65.

What that analysis cannot tell us

• It is observational, not a randomized trial. The authors say residual confounding is possible and that all estimates warrant caution.
• The authors say it should not be used to support hormone therapy for preventing heart disease, given "the inconsistency of the cardiovascular benefits and the need to consider overall risk-benefit balance."
• Events were largely self-reported (heart attack, stroke, heart failure, and revascularization); cardiovascular deaths came from death certificates.
• The later-start estimate is imprecise. That interval is wide and crosses 1. "No clear effect" is not proof of harm, or of safety, after a late start.
• It does not, by itself, answer the 60- and 65-year questions. The women who started therapy had a mean age of 53.7 years. The 10-year window is measured from "the onset of menopause," not a birthday, and the analysis is about initiation—not a rule for continuing or stopping at a given age.
• We are working from the abstract. Details that may live only in the full paper—such as exact definitions, doses, and formulations—are not used here.

Hormone therapy is for symptom care when it is appropriate. It is not a pill that prevents heart disease, dementia, or aging.

What FDA labeling currently says

In November 2025, FDA asked manufacturers of menopausal hormone therapies to remove language about cardiovascular diseases, breast cancer, and probable dementia from the boxed warning and to retain the endometrial-cancer boxed warning on systemic estrogen-alone products. For systemic products, FDA asked that information about cardiovascular disease and breast cancer warnings remain in the labeling, and that labels add consideration of starting hormone therapy for moderate to severe vasomotor symptoms (hot flashes) in women younger than 60 or less than 10 years since menopause. "Removed from the boxed warning" is not "no risks."

As of FDA's product list, content current as of October 30, 2026, updated prescribing information has been approved for nine products: Prometrium (progestogen alone); Divigel, Cenestin, Enjuvia, Minivelle, Vivelle, and Vivelle-Dot (systemic estrogen alone); Estring (topical vaginal estrogen); and Bijuva (systemic estrogen and progestogen). If your product is not on that list, its label may not have changed yet. See our boxed-warning explainer for what those changes did and didn't do.

Two points matter for the age-limit question. First, the younger-than-60 or less-than-10-years language FDA asked to add is about starting therapy for bothersome hot flashes—not a requirement to stop at 60. Second, FDA also asked companies to remove, from the boxed warning, the recommendation to use the lowest effective dose for the shortest amount of time. That is a wording change, not a recommendation to stay on therapy indefinitely. Dose and duration still belong in a conversation with your clinician.

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus. People who have a uterus and use systemic estrogen typically still need a progestogen. Naming a product here does not mean Kindr Health prescribes it.

What ACOG says—and doesn't say—about 60 and 65

In October 2026, the American College of Obstetricians and Gynecologists (ACOG) published expanded clinical guidance on menopause symptoms, which we covered when it came out. From ACOG's October 15 news page:

ACOG recommends that initiating hormone therapy be based on shared decision-making, considering the patient's symptoms; the benefits and risks based on age, medical history, and baseline risks of cardiovascular disease, breast cancer, and venous thromboembolism (blood clots); and individualized treatment goals. If selected, ACOG recommends initiating hormone therapy before age 60 or within 10 years of the start of spontaneous (natural) menopause, in people without contraindications. That is timing for symptom care, not a claim that hormone therapy prevents heart disease, dementia, or aging.

On continuing, that news page does not set a mandatory stop at 60 or 65. It says decisions about when and how to discontinue hormone therapy should be individualized, based on ongoing risk-factor assessment and a discussion between a patient and their clinician about benefits and risks. The page does not mention age 65 as a cutoff, and it does not say therapy must be stopped at 60. That is a call to talk with a clinician about benefits and risks—not a finding that therapy is risk-free at older ages, and not a blanket stop rule.

What The Menopause Society's 2022 position statement says about 60 and 65

The "stop by 65" shorthand is often associated with the American Geriatrics Society Beers Criteria, which include warnings against hormone therapy in women older than 65. The Menopause Society's 2022 hormone therapy position statement (published when the organization was The North American Menopause Society) addresses that point directly. It says there is no general rule for stopping systemic hormone therapy at age 65. In the Society's words, "the recommendation to routinely discontinue systemic hormone therapy in women aged 65 years and older is neither cited or supported by evidence nor is it recommended" by ACOG or The Menopause Society. A Level III key point in that statement is that hormone therapy "does not need to be routinely discontinued in women aged older than 60 or 65 years."

That is not a finding that therapy is risk-free after 60 or 65, and it is not advice to stay on therapy. The same statement notes that continued use of hormone therapy in healthy women older than 65 at low risk for breast cancer and cardiovascular disease "is limited by insufficient evidence regarding safety, risks, and benefits." On when to start, it says the benefit-risk ratio is favorable for treating bothersome hot flashes and night sweats in women younger than 60 or within 10 years of menopause onset and with no contraindications, and appears less favorable when therapy is started after age 60 or more than 10 years from menopause onset, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism (blood clots), and dementia. Whether to start, continue, or stop belongs in a conversation with a clinician, with periodic reassessment.

An upcoming session on women 65 and older

On November 11, 2026, The Menopause Society (@MenopauseOrg) announced that the December episode of its Menopause Step-by-Step webinar series will be held on Wednesday, December 2, 2026. According to the post, host Dr. Stephanie Faubion and guest Dr. Tara Iyer will discuss "Hormone Therapy Considerations in Women Aged 65 Years and Older." The post pointed to The Menopause Society's site for more information. We are not going to invent what the session will say: it has not happened yet. An announced professional-education session is not new clinical guidance, and it is not a finding about safety or harm after 65.

Questions to bring to a clinician

This article does not advise you to start, stop, or change any medicine. Those decisions belong with you and a licensed clinician. Useful questions:

1. Is hormone therapy appropriate for me? Given my symptoms, age, time since menopause, and health history—including blood clots, stroke, heart attack, breast cancer, liver disease, or unexplained bleeding—does starting or continuing make sense?
2. If we use it, what dose and what route—and why? A pill, patch, gel, or local vaginal treatment is not interchangeable; each has different uses and risk profiles.
3. How long might I take it, and when will we reassess? Ask what you would review together, and how often, to decide whether to continue, change the dose or route, or stop.
4. If I am already 60 or 65, or will be soon, what would continuing look like? Starting-window guidance is not automatically a stop rule. Ask how my age and timing enter this decision, and what would lead us to change course.
5. What should I watch for, and what else is on the table? Ask about side effects and warning signs, and about nonhormonal options if hormones are not suitable or not preferred.

Where Kindr fits

At Kindr Health, menopause and midlife care is clinician-led. Conversations about hormone therapy are individualized: your symptoms, age, timing, health history, and goals—not a single age cutoff. Kindr Health is a telehealth platform that connects patients with licensed clinicians, who can talk through whether hormone therapy is appropriate for you. Being over 60 or 65 is not an automatic yes or no: risks generally rise with age and with time since menopause, and a clinician weighs your individual benefits and risks. Kindr Care patient intake is open now.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 12, 2026